Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

VEGFR3 inhibitor EVT801

An orally bioavailable, small molecule inhibitor of human vascular endothelial growth factor receptor 3 (VEGFR3; VEGFR-3; Flt-4), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, VEGFR3 inhibitor EVT801 specifically targets, binds to and inhibits VEGFR3 tyrosine kinase, which may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. EVT801 may also decrease the level of immune suppressive myeloid derived suppressor cells (MDSCs) in the blood, thereby activating anti-tumor immune responses. VEGFR3 plays a critical role in the embryonic vascular system development but is restricted postnatally to endothelial cells of lymphatic vessels and found to be expressed in many solid and hematologic malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:EVT 801
EVT-801
EVT801
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search